Comparative Pharmacology
Head-to-head clinical analysis: ANCOBON versus MICONAZOLE NITRATE COMBINATION PACK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANCOBON versus MICONAZOLE NITRATE COMBINATION PACK.
ANCOBON vs MICONAZOLE NITRATE COMBINATION PACK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Flucytosine is converted intracellularly to 5-fluorouracil, which inhibits fungal RNA and DNA synthesis by incorporating into RNA and inhibiting thymidylate synthase.
Miconazole nitrate inhibits fungal lanosterol 14α-demethylase (CYP51), disrupting ergosterol synthesis and causing fungal cell membrane damage.
50-150 mg/kg/day orally divided every 6 hours; intravenous dosing: 50-150 mg/kg/day divided every 12 hours.
Intravaginally, one suppository (100 mg miconazole nitrate) once daily at bedtime for 7 days or one suppository (200 mg) once daily for 3 days, combined with topical application of miconazole nitrate cream (2%) to the vulvar area twice daily for 7 days.
None Documented
None Documented
Terminal elimination half-life 2.5-6 hours (normal renal function). Prolonged to 30-250 hours in renal impairment (CrCl < 20 mL/min). Half-life correlates with creatinine clearance.
Terminal elimination half-life is approximately 20-25 hours, but can be prolonged to 30-40 hours in patients with hepatic impairment.
Primarily renal excretion of unchanged drug (75-90% within 24 hours). Less than 1% eliminated as 5-fluorouracil metabolite. Biliary/fecal excretion negligible.
Primarily fecal (biliary) as unchanged drug and metabolites (~50-60%); renal excretion accounts for <20% of the dose, mostly as inactive metabolites.
Category C
Category A/B
Antifungal
Antifungal